Grid Therapeutics, a US-based oncology-focused spinout from Duke University, has closed a series A round of undisclosed size from investors including the institution’s TTO, Office of Licensing and Ventures.
The round was led by venture capital firm Longview International.
Grid Therapeutics has developed technology to obtain antibodies capable of killing early-stage cancer tumours. The antibodies, which have displayed no side effects so far, are held within a patient’s own single B cells, a variety of the white blood cell which…
